Search research articles
Contact Us
Filters
Showing results (221-230 of 280) with videos related to
Page
of 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2017
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
Frances A Shepherd, Benjamin Lacas, Gwénaël Le Teuff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 23, 2016
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
Xiaoli Ma, Gwénaël Le Teuff, Benjamin Lacas, et al.
Science Translational Medicine
|
May 24, 2013
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers
Sophie Rousseaux, Alexandra Debernardi, Baptiste Jacquiau, et al.
Carcinogenesis
|
December 17, 2013
Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures
Charlotte Sagne, Virginie Marcel, Maria Bota, et al.
Human Mutation
|
April 19, 2019
Response to: Concern regarding classification of germlineTP53 variants as likely pathogenic
Kelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 8, 2018
ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
Anne McLeer-Florin, Michael Duruisseaux, Julian Pinsolle, et al.
Human Mutation
|
October 24, 2018
Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis
Kelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Lancet Regional Health. Americas
|
February 3, 2025
Personalized screening strategies for <i>TP53</i> R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers
Pedro A F Galante, Gabriela D A Guardia, Janina Pisani, et al.
Cancer Research
|
October 28, 2010
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma
Johannes Voortman, Akiteru Goto, Jean Mendiboure, et al.
Breast Cancer Research : BCR
|
May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
Lynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 280) with videos related to
Sort By:
Page
of 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2017
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
Frances A Shepherd, Benjamin Lacas, Gwénaël Le Teuff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 23, 2016
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
Xiaoli Ma, Gwénaël Le Teuff, Benjamin Lacas, et al.
Science Translational Medicine
|
May 24, 2013
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers
Sophie Rousseaux, Alexandra Debernardi, Baptiste Jacquiau, et al.
Carcinogenesis
|
December 17, 2013
Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures
Charlotte Sagne, Virginie Marcel, Maria Bota, et al.
Human Mutation
|
April 19, 2019
Response to: Concern regarding classification of germlineTP53 variants as likely pathogenic
Kelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 8, 2018
ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
Anne McLeer-Florin, Michael Duruisseaux, Julian Pinsolle, et al.
Human Mutation
|
October 24, 2018
Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis
Kelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Lancet Regional Health. Americas
|
February 3, 2025
Personalized screening strategies for <i>TP53</i> R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers
Pedro A F Galante, Gabriela D A Guardia, Janina Pisani, et al.
Cancer Research
|
October 28, 2010
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma
Johannes Voortman, Akiteru Goto, Jean Mendiboure, et al.
Breast Cancer Research : BCR
|
May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
Lynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Page
of 28